Nicholas Investment Partners’s Vaxcyte PCVX Stock Holding History

Nicholas Investment Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.62M	Buy	+131,133	New	+$7.12M	0.43%	82
2025 Q2	–	Sell	-116,229	Closed	-$4.39M	–	226
2025 Q1	$4.39M	Buy	116,229 +15,922	+16%	+$1.27M	0.45%	92
2024 Q4	$8.21M	Buy	100,307 +18,424	+23%	+$1.83M	0.72%	40
2024 Q3	$9.36M	Sell	81,883 -5,347	-6%	-$482K	0.86%	33
2024 Q2	$6.59M	Buy	87,230 +1,586	+2%	+$108K	0.68%	44
2024 Q1	$5.85M	Sell	85,644 -25,079	-23%	-$1.74M	0.6%	56
2023 Q4	$6.95M	Sell	110,723 -349,285	-76%	-$18.1M	0.81%	33
2023 Q3	$23.5M	Sell	460,008 -156	-0%	-$7.7K	1.75%	16
2023 Q2	$23M	Buy	460,164 +26,364	+6%	+$1.25M	1.57%	20
2023 Q1	$16.3M	Buy	433,800 +310,478	+252%	+$13.2M	1.24%	29
2022 Q4	$5.91M	Buy	+123,322	New	+$4.84M	0.52%	61

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Nicholas Investment Partners's PCVX Position: Q2 2026 in Review

Nicholas Investment Partners opened a new position in Vaxcyte (PCVX) in Q2 2026: 131,133 shares worth $7.62M. The stake represents 0.43% of the portfolio and ranks #82 among its holdings. This is a return to the name: Nicholas Investment Partners previously reported a position in PCVX as recently as Q1 2025.

Nicholas Investment Partners first reported a position in PCVX in Q4 2022 and has held it in 11 quarters since. The position peaked at $23.5M in Q3 2023. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Nicholas Investment Partners held 131,133 shares of Vaxcyte worth $7.62M as of Q2 2026.
Vaxcyte was a new Nicholas Investment Partners position in Q2 2026.
Vaxcyte made up 0.43% of Nicholas Investment Partners's portfolio in Q2 2026, its #82 holding.
Nicholas Investment Partners first reported a position in Vaxcyte in Q4 2022 and has held it in 11 quarters since.
Nicholas Investment Partners's Vaxcyte position peaked at $23.5M in Q3 2023.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.